Middle East Prefilled Syringes Market (2025 - 2033)

Middle East Prefilled Syringes Market Summary

The Middle East prefilled syringes market size was estimated at USD 126.4 million in 2024 and is projected to reach USD 253.4 million by 2033, growing at a CAGR of 8.10% from 2025 to 2033. The increase in chronic diseases in the Middle East region, such as cancer, and a growing focus on early disease diagnosis and chronic disease management, continue to increase demand for safer and more efficient drug delivery systems like prefilled syringes.

Furthermore, government initiatives to widen reimbursement coverage and access to healthcare have increased the prospects for mindful use of prefilled syringes in hospitals and across various sectors, especially in Gulf countries, which have successfully improved their healthcare infrastructure.

The Middle East has witnessed a notable increase in product entries and strategic expansions by leading pharmaceutical companies in recent months. For instance, in May 2025, Pfizer launched the region’s first prefilled autoinjector therapy for hemophilia in the UAE, providing patients with a once-weekly, self-administered treatment that reduces hospital visits and improves convenience. This initiative aims to enhance access to advanced injectable therapies, but the key takeaway is the increasing use of patient-friendly drug delivery systems in the region.

The medical device markets in the region are the largest in the United Arab Emirates and Saudi Arabia. Ongoing disease burden, rising healthcare expenditures, and greater privatization in healthcare are some of the major drivers expected to boost the prefilled syringe industry throughout this forecast period.

The prevalence of chronic diseases in the Middle East is significant, primarily diabetes, and this increases the demand for prefilled syringes. Moreover, patients with diabetes often rely on prefilled syringes due to the convenience and easy usage associated with these products. One of the key benefits of these syringes is their enhanced dose accuracy, along with the decreased risk of contamination. As chronic disease continues to grow in this region, prefilled syringes will likely be more frequently adopted by both patients and healthcare providers, thus fueling market growth.

Along with this rising demand, the manufacturing companies in the Middle East are expanding local production and distribution of prefilled syringes. For instance, Al Shifa Medical Syringe Manufacturing Co. in Saudi Arabia produces prefilled syringes with sterile saline solutions, Julphar in the UAE offers a range of prefilled injectable therapies, and Fresenius Kabi provides its Simplist prefilled syringes across the region. These initiatives highlight the strategic efforts of manufacturers to meet growing healthcare needs and improve access to advanced drug delivery systems in the Middle East.

Top Companies Providing Prefilled Syringes

Source: Company Websites, GVR Analysis

Market Concentration & Characteristics

A growing number of international and regional producers are present in the Middle East prefilled syringes industry, along with an increase in patient demand and the demand for new drug delivery systems to reduce inconvenience in medication use. The UAE, and Saudi Arabia, are centralizing health infrastructure. These countries, among others, have discussed government programs aimed at improving access to medical devices.

The Middle East prefilled syringes industry is experiencing steady innovation, accelerated by advanced syringe designs and safer, more efficient delivery systems. For instance, the report was published by Harvard Innovation Labs in November 2024, stating that Pacto Medical developed a compact, carbon-friendly prefilled syringe that reduces packaging volume by 40%, lowering storage and transportation costs while minimizing environmental impact. Clinics and hospitals in countries like Saudi Arabia and the UAE are increasingly adopting such advanced syringes, which shows the move towards products that are more reliable, easy to use, and environmentally friendly. This focus on innovative, eco-conscious products positions innovation as a key factor shaping competitive differentiation in the region.

The Middle East prefilled syringes industry is also being influenced by strategic mergers and acquisitions among the companies, ultimately reflecting on rising investor interest in injectables and advanced drug delivery systems. For instance, Abu Dhabi–based investment and holding company ADQ acquired 100% of Turkish pharmaceutical manufacturer Birgi Mefar Group (BMG), a leading producer of sterile injectable products such as vials and prefilled syringes for vaccines. The deal, which was signed in June 2024 and pending regulatory approvals, will see BMG join ADQ’s Healthcare and Life Sciences portfolio, giving the Abu Dhabi firm direct access to a fast-growing market segment while strengthening its position in the global value chain for injectables.

Regulation holds a major impact in the Middle East prefilled syringes industry. Countries, such as the UAE and Saudi Arabia, along with organizations such as the Gulf Cooperation Council, have made stringent regulations around factors such as manufacturing standards, product approvals, and distribution to ensure patient safety. Regulatory bodies have been following global best practices closely and are strictly requiring compliance with sterility and quality standards. Regulation is a key factor that helps to manage and limit the opportunity for unsafe or counterfeit products to exist while enabling innovation. Stronger approval systems create trust, enable faster uptake, and increase integrity in the region's healthcare.

In the rising demand for modern drug delivery systems, traditional injections are still widely used across hospitals and clinics due to their price affordability, broad availability, and familiarity among healthcare professionals. In many low- and middle-income parts of the region, limited awareness about advanced prefilled solutions and a shortage of skilled staff further reinforce reliance on traditional injection methods. However, while traditional injections offer affordability and flexibility, they also carry higher risks of contamination, dosing errors, and needle-stick injuries compared to prefilled syringes.

The Middle Eastern region is undergoing rapid growth, supported by continuous investment in advanced medical technologies and stronger healthcare infrastructure. Countries such as the UAE and Saudi Arabia are taking the lead, positioning themselves as regional hubs for innovative drug delivery solutions, like prefilled syringes. This expansion reflects not only the modernization of healthcare systems but also the rising demand for safer, more efficient injectable therapies across the Middle East.

Type Insights

The disposable segment accounted for the largest market revenue share in 2024 and is projected to grow at the fastest CAGR over the forecast period. The rising adoption of self-injectable medications has increased the need for safety in syringe usage. Disposable syringes help in limiting this concern by reducing the risk of cross-contamination. Their role is particularly critical in diagnostic and therapeutic applications for chronic diseases, where safe and efficient medication delivery is essential, driving demand in the Middle East market. In addition, the region's rising prevalence of lifestyle-related conditions and growing awareness about infection control are further accelerating adoption. The shift toward safer, more reliable solutions is expected to reinforce the dominance of disposable prefilled syringes in the coming years.

The reusable segment is expected to grow at a modest CAGR of 3.83% over the forecast period. These syringes can be used repeatedly on a patient's use, when they have disposable tips, which is making them cost effective along with reducing the chances of infections while adhering to safety procedures. In addition, they are designed to improve resource use in healthcare environments, since they reduce the overall volume of medical waste.

Material Insights

The glass segment led the market with the largest revenue share of 81.35% in 2024. Glass provides a strong barrier against environmental factors such as moisture, oxygen, and light, which is crucial for maintaining the stability and integrity of medications. Its superior protective qualities make it more reliable than many plastic alternatives, particularly for drugs sensitive to external conditions. Furthermore, the high clarity of glass syringes enables healthcare professionals to clearly inspect and administer the medication with confidence. In addition to these benefits, glass is chemically inert, reducing the chances of interaction between the container and the drug solution. The long-established trust in glass for pharmaceutical applications continues to reinforce its dominance in the market.

The plastic segment is anticipated to grow at the fastest CAGR of 9.82% over the forecast period. Plastic syringes are a very affordable alternative to glass because of their lower material and production costs. This affordability makes prefilled syringes more accessible for different levels of healthcare facilities. Apart from price, plastic also provides flexibility in design, making the creation of advanced features like multi-chamber formats or built-in needle guards that improve both safety and ease of use. These benefits are expected to drive stronger demand for plastic prefilled syringes in the years ahead.

Application Insights

The vaccines segment led the market with the largest revenue share of 38.95% in 2024. Typically, many vaccines require multiple doses over time, and prefilled syringes are the better choice because they remove the risk for the healthcare provider from drawing medication out of a vial, therefore decreasing the contamination and error potential. When patients receive vaccines voluntarily, prefilled syringes ensure that they are measured out and labeled packages for easier and safer administration while adhering to high immunization practices within the area.

The autoimmune disease segment is anticipated to grow at the fastest CAGR during the forecast period. Many treatments for autoimmune conditions require frequent injections. When patients are navigating therapies with prefilled syringes, they get benefits. Transporting and administering therapy from a regular vial and syringe is difficult due to the procedures involved, and many of these treatments take place at home for patient comfort. According to many studies, convenient prefilled syringes of medications maximize engagement and autonomy for patients. Along those lines, there are now also new advanced prefilled syringe designs, such as a multi-chamber system prefilled syringe that can support combination therapy, which is prescribed for some autoimmune treatments, thus allowing patients greater freedom and comfort in their own accommodations.

Distribution Channel Insights

The hospitals segment led the market with the largest revenue share of 72.24% in 2024. Hospitals are usually the preferred choice for patients because of their accessibility and established trust. The use of prefilled syringes in hospital settings enhances safety and efficiency, reducing the risk of errors and providing a reliable option for healthcare providers. In addition, prefilled syringes help streamline workflow in busy hospital environments, which allows staff to focus more on patient care. Their ready-to-use design also minimizes preparation time and ensures accurate dosing, contributing to overall treatment quality and patient confidence.

The mail order pharmacies segment is projected to experience at the fastest CAGR of 9.04 over the forecast period. These pharmacies provide patients with the convenience of having medications delivered directly to their homes, which is especially helpful for those who require regular injections with prefilled syringes. In addition to saving time and reducing the need for frequent pharmacy visits, mail order pharmacies often offer competitive pricing, making treatment more affordable. These benefits are particularly valuable for patients with chronic conditions who depend on ongoing medication, contributing to the expected growth of this segment.

Country Insights

Saudi Arabia dominated the Middle East prefilled syringes market with the largest revenue share of 49.34% in 2024, driven by the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and diabetes. These conditions are creating a strong demand for safer and more efficient drug delivery systems. Non-communicable diseases account for the majority of deaths in the country, highlighting the urgent need for reliable treatment options. Prefilled syringes offer improved safety, dose accuracy, and convenience, making them increasingly relevant to the Saudi healthcare system. Although awareness and adoption remain relatively low, companies are focusing on technological advancements and tailored product launches to address the specific needs of the Kingdom’s healthcare sector. With ongoing improvements in infrastructure and patient access, the use of prefilled syringes is expected to expand further in the coming years.

Qatar Prefilled Syringes Market Trends

The prefilled syringes market in Qatar is anticipated to grow at a substantial CAGR during the forecast period. The need for prefilled syringes is growing in Qatar, due to the higher incidence of chronic diseases associated with lifestyle habits, including diabetes, a range of cardiovascular diseases, and obesity-related diseases. The number of adults with type 2 diabetes is expected to climb to 597,000 by 2050. The rise in chronic disease suggests a pressing need for safer and more effective drug delivery systems. Prefilled syringes permit improved safety, exact dosing, and convenience, making them an important component of chronic disease management. To address the rising burden of noncommunicable diseases in its population, healthcare providers have embraced using prefilled syringes to improve compliance and treatment outcomes.

Oman Prefilled Syringes Market Trends

The Oman prefilled syringes market is expected to grow at a rapid CAGR during the forecast period. The burden of noncommunicable diseases (NCDs), such as cardiovascular diseases, diabetes, chronic respiratory disorders, and cancer, has been growing in Oman. NCDs are responsible for 83% of all deaths in Oman; together they represent four of the ten leading causes of premature mortality (Kingdom of Oman Ministry of Health, 2020). Rising obesity, hypertension, and dyslipidemias lead to an increased burden of chronic conditions, and in an adult population, represent the increased demand for an increasing number of patients that need regular and accurate doses of medications (more so with diabetes and asthma). The increasing demand provides a requirement for a safer and more effective delivery system. Prefilled syringes are an excellent option with many benefits: accurate dosing, safety, and convenience, especially with chronic conditions. With the Ministry of Health (MOH) in Oman providing expanded access to NCD clinics and now the MOH and other organizations opening specialized asthma and diabetes centers in primary care and within a tertiary facility, coupled with a rationalization of the use of prefilled syringes in Oman, will have many benefits for improved outcomes, including adherence with long-term therapy.

UAE Prefilled Syringes Market Trends

The prefilled syringes market in the UAE is witnessing notable growth, supported by strong healthcare infrastructure, a rising number of hospitals, and expanding medical tourism. Efficient health coverage policies and growing awareness of minimally invasive procedures, particularly among the younger population, are further boosting adoption. The country faces a high burden of chronic diseases, with diabetes prevalence among the highest globally at 16.3%, alongside increasing cases of cardiovascular disorders. A study by Cleveland Clinic Abu Dhabi revealed that more than half of UAE citizens have been directly affected by heart disease, making it the leading cause of mortality in the nation. These factors are driving demand for reliable and advanced drug delivery solutions such as prefilled syringes, supported by rapid technological advancements that enhance safety and usability.

Kuwait Prefilled Syringes Filler Market Trends

The Kuwait prefilled syringes market is experiencing growth, driven by the country’s focus on adopting advanced medical technologies and improving healthcare delivery. The rising prevalence of chronic diseases, including respiratory conditions and diabetes, is fueling demand for reliable injectable solutions. Studies indicate that 7.1% of the population suffers from COPD, with a hospitalization rate of 22.5%, while approximately 25% of individuals have at least one noncommunicable disease (NCD). Diabetes prevalence is particularly high at 22%, more than double the global average, and around one-fourth of the population lives with two or more chronic conditions. This growing burden of chronic diseases is expected to boost the adoption of prefilled syringes and expand the market in Kuwait.

Key Middle East Prefilled Syringes Company Insights

Leading players such as BD, Gerresheimer AG, and SCHOTT Pharma AG are propelling the market growth in the Middle East. These companies leverage advanced technologies, innovative formulations, and targeted marketing to enhance product efficacy and appeal. Their strategic expansions and strong distribution networks are boosting accessibility, meeting rising consumer demand for minimally invasive aesthetic treatments, and solidifying their competitive presence in the region’s rapidly evolving beauty and wellness sector.

Recent Developments

• In October 2024, BD entered into a strategic collaboration with Ypsomed, a prominent manufacturer of injection systems, aimed at advancing self-injection options for high-viscosity biologic therapies. As part of this initiative, the two companies conducted a joint assessment and successfully aligned BD’s Neopak XtraFlow Glass Prefillable Syringe with Ypsomed’s YpsoMate 2.25 autoinjector platform. The partnership is designed to overcome existing market challenges by enabling reliable and convenient administration of biologic drugs with viscosities above 15 cP using an autoinjector format.

• On September 18, 2024, BD (Becton, Dickinson and Company) launched the BD Neopak XtraFlow Glass Prefillable Syringe, designed to improve the subcutaneous delivery of higher viscosity biologic drugs by reducing injection force and time.

Middle East Prefilled Syringes Market